Abstract
Inhibition of the integrin-linked kinase (ILK) pathway represents a novel target in ovarian cancer treatment
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have